Table 1. Main Features of Studies Incorporated in the Meta-Analysis.

Study	Williams et al, 2017 [15]	Supasyndh et al, 2017 [16]	Schmieder et al, 2017 [17]	Wang et al, 2017 [14]	Izzo et al, 2017 [13]
Type of study	Monotherapy only, drug comparison, multicenter	Monotherapy only, drug comparison, multicenter	Monotherapy or combination therapy with amlodipine, drug comparison, multicenter	Monotherapy only, drug comparison, multicenter	Monotherapy only, drug comparison, multicenter
Blind	DB	DB	DB	DB	DB
RCT	Yes	Yes	Yes	Yes	Yes
Comparisons	Sacub/v vs. olmesartan	Sacub/v vs. olmesartan	Sacub/v vs. olmesartan	Sacub/v vs. valsartan	Sacub/v vs. valsartan
Number of patients	454	588	114	72	285
Study duration (weeks)	12 - 52	14	12 - 52	4	8
Doses of sacubitril/valsartan per day	200 or 400 mg	100, 200 or 400 mg	200 or 400 mg plus optional amlodipine, up to 10 mg QD, only if needed for BP control	400 mg	400 mg
Doses of ARB per day	20 or 40 mg (a)	10, 20 or 40 mg (a)	20 or 40 mg (a) plus optional amlodipine, up to 10 mg QD, only if needed for BP control	320 mg (b)	320 mg (b)

(a) Olmesartan was used as a comparator drug. (b) Valsartan was used as a comparator drug. DB: double blind; RCT: randomized controlled trial; ARB: angiotensin receptor blocker; QD: every day; BP: blood pressure.